Chemistry:Serlopitant
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C29H28F7NO2 |
| Molar mass | 555.537 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Serlopitant (INN,[1] codenamed VPD-737) is a drug which acts as an NK1 receptor antagonist. It was assessed in clinical trials for the treatment of urinary incontinence and overactive bladder, but while it was superior to placebo it provided no advantage over existing approved drugs, and was not approved for further development for this indication.[2][3] Serlopitant is now undergoing clinical trials for the treatment of chronic pruritus (itch)[4]
See also
- NK1 receptor antagonist
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 62". World Health Organization. 2009. pp. 261–2. https://www.who.int/medicines/publications/druginformation/innlists/RL62.pdf.
- ↑ "A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder". The Journal of Urology 184 (2): 616–22. August 2010. doi:10.1016/j.juro.2010.03.147. PMID 20639026.
- ↑ "Urinary incontinence: Neurokinin receptor antagonist inferior to tolterodine for OAB". Nature Reviews. Urology 7 (8): 418. August 2010. doi:10.1038/nrurol.2010.105. PMID 20726068.
- ↑ "For Irritating Itch, a Promising Option Under Scrutiny". http://www.medscape.com/viewarticle/885765#vp_2.
 |  |
